pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics in efficacy analysis set

Characteristic Nivolumab (n=40) Pembrolizumab (n=18) p-value
Median age, Mean±SD 72, 72.2±3.1 70.5, 72.3±5.1 0.934

Age (%) 0.438
60~75 35 (87.5%) 14 (77.8%)
76~ 5 (12.5%) 4 (22.2%)

ECOG performance status-n. (%) 1.000
0 25 (62.5%) 12 (66.7%)
1 10 (25.0%) 4 (22.2%)
2 4 (10.0%) 1 (5.6%)
3 1 (2.5%) 1 (5.6%)

Cancer type n. (%) 0.548
not NSCLC 16 (40.0%) 5 (27.8%)
NSCLC 24 (60.0%) 13 (72.2%)

Cancer stage-n. (%) 0.081
I~II 4 (10.0%) 2 (11.1%)
III 8 (20.0%) 6 (33.3%)
IV 27 (67.5%) 7 (38.9%)
unknown 1 (2.5%) 3 (16.7%)

No of metastatic sites n (%) 0.438
0 5 (12.5%) 4 (22.2%)
≥1 35 (77.5%) 14 (77.8%)

Metastatic site-n. (%)
brain 8 (20.0%) 3 (16.7%) 1.000
liver 4 (10.0%) 2 (11.1%) 1.000
lung 10 (25.0%) 0 (0.0%) 0.023
lymph node 7 (17.5%) 1 (5.6%) 0.413
bone 9 (22.5%) 2 (11.1%) 0.474
adrenal gland 4 (10.0%) 1 (5.6%) 1.000
other 6 (15.0%) 1 (5.6%) 0.417

Prior chemotherapy -n. (%) 0.339
0 2 (5.0%) 3 (16.7%)
1 10 (25.0%) 6 (33.3%)
2 15 (37.5%) 6 (33.3%)
≥3 13 (32.5%) 3 (16.7%)

Presence of radiotherapy (%) 20 (50.0%) 11 (61.1%) 0.617

PD-L1 expression-n. (%)
<10% 26 (65.0%) 5 (27.8%) <0.001
10% ≤ X <50% 8 (20.0%) 0.011
≥50% 6 (15.0%) 13 (72.2%) <0.001

SD, Standard deviation; ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer; PD-L1, Programmed death-ligand 1

Korean J Clin Pharm 2020;30:11-8 https://doi.org/10.24304/kjcp.2020.30.1.11
© 2020 Korean J Clin Pharm